Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DB25FSDPE
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $75,270
Award facts
- Contract value 100% obligated
- $75,269.76 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a firm fixed price ceiling value of $75,269.76 and ultimate completion date of August 26, 2025. This non-set-aside, competitively awarded delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 million global pharmaceutical support vehicle that runs through December 2026. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a major pharmaceutical distributor and critical vendor for federal medical procurement.
As a child contract under the broader IDC vehicle, this delivery order exemplifies AmerisourceBergen's role in supporting military healthcare programs through the supply of specialty medications and brand-name pharmaceuticals. Dupixent (dupilumab) is a prescription biologic used to treat moderate-to-severe eczema, asthma, and other allergic conditions, representing the type of specialized medical commodities that AmerisourceBergen routinely procures for the Defense Health Agency and other federal healthcare systems. The company's comprehensive portfolio and demonstrated capability to fulfill federal medical supply requirements across multiple therapeutic domains have positioned it as a prime vendor within the DLA's pharmaceutical supply chain infrastructure.
Quick answers
Who was awarded contract SPE2DB25FSDPE?
SPE2DB25FSDPE was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 25, 2025.
How much is contract SPE2DB25FSDPE worth?
The government has obligated $75,270 on SPE2DB25FSDPE.
Is contract SPE2DB25FSDPE an order under another contract?
Yes. SPE2DB25FSDPE is a delivery order under SPE2DB22D2211, an indefinite delivery contract.
Was contract SPE2DB25FSDPE competed?
The extent of competition for SPE2DB25FSDPE was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award